FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38914020.
- Also identified by DOI 10.1097/RLU.0000000000005318.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
With the increase in use of GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) in the population, nuclear medicine physicians should be aware of the possibility of nondiagnostic FDG PET scans due to these medications, which work partly by increasing insulin secretion. We demonstrate a case where a patient's use of such a medication presumptively led to muscular and myocardial uptake, complicating scan interpretation considerably. Clinicians should be aware of the presence of these drugs and their potential effect on biodistribution in FDG PET. Further study is needed to best understand the effects of these medications on FDG biodistribution.
Medical subject headings
- Fluorodeoxyglucose F18
- Positron-Emission Tomography